VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
5733
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
918
Interactions with Platform & by Email
PARTICIPANTS
172
Unique # Participated
VALIDATIONS
77
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
144
PAGES
267
EDITION
19
PRICE
USD $5450
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the Acute Heart Failure (AHF) Therapeutics Market?
COVID-19 IMPACT SURVEY
GLOBAL EXECUTIVE SURVEY
Impact of Pandemic & Economic Slowdown
Monitor Market Dynamics!
Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.
Amid the COVID-19 crisis, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$372.9 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 22.2% over the analysis period 2020-2027. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$391 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the B-Blockers segment is readjusted to a revised 25.6% CAGR for the next 7-year period.
The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$100.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$363.8 Million by the year 2027 trailing a CAGR of 27.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.5% and 20.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19% CAGR.
In the global Calcium Channel Blockers segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$42.6 Million in the year 2020 will reach a projected size of US$184.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$226.8 Million by the year 2027, while Latin America will expand at a 25.5% CAGR through the analysis period. We bring years of research experience to this 19th edition of our report. The 267-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Bayer AG; Bristol-Myers Squibb Company; Cardiorentis AG; CVie Therapeutics Limited; Cytokinetics, Inc.; Merck & Co., Inc.; Novartis AG; Orion Corporation; PhaseBio Pharmaceuticals, Inc.
» Product Type (Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics, Other Product Types) » End-Use (Home Care, Hospitals, Clinics, Other End-Uses)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Market Outlook |
| Recent Market Activity |
| Sizing the AHF Market |
| Acute Heart Failure - An Overview of the Disease and Available Therapeutics |
| Diuretics and Vasodilators - The First Line Therapy for AHF |
| Other Known Drugs for AHF - Lower Efficacy Thwarts Use |
| Global Competitor Market Shares |
| Acute Heart Failure (AHF) Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Bayer AG (Germany) |
| Bristol-Myers Squibb Company (USA) |
| Cardiorentis AG (Switzerland) |
| CVie Therapeutics Limited (Taiwan) |
| Cytokinetics, Inc. (USA) |
| Merck & Co. (USA) |
| Novartis AG (Switzerland) |
| Orion Corporation (Finland) |
| PhaseBio Pharmaceuticals, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Conventional Therapies Leave Considerable Unmet Needs |
| Novel Treatments Offer a Ray of Hope |
| Key AHF Therapeutics in the Pipeline |
| Serelaxin Nears Trial Readout form RELAX-AHF-2 |
| Ularitide - A Novel Drug in Development for AHF |
| The Litany of Drug Failures Expands, Emphasis on Prevention Grows |
| Other Promising Drugs under Development |
| Research Findings |
| Kidney Dysfunction - Predictor of Acute Heart failure |
| Genetic Influence on Heart Disease among African Americans |
| Higher Body Mass Index - A Key Risk Factor for AHF |
| Supplemental Oxygen Therapy May not be for All Cases of AHF |
| Macro Growth Drivers |
| Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics |
| Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics |
| 4. GLOBAL MARKET PERSPECTIVE |
| Acute Heart Failure (AHF) Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Shift across Key Geographies Worldwide: 2019 VS 2025 |
| Cardiac Glycosides (Product Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Cardiac Glycosides (Product Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2019 VS 2025 |
| B-Blockers (Product Type) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| B-Blockers (Product Type) Market Sales Breakdown by Region/Country in Percentage: 2019 VS 2025 |
| Calcium Channel Blockers (Product Type) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Calcium Channel Blockers (Product Type) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025 |
| Diuretics (Product Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Diuretics (Product Type) Market Share Breakdown by Region/Country: 2019 VS 2025 |
| Other Product Types (Product Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Other Product Types (Product Type) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025 |
| Home Care (End-Use) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2018 through 2025 |
| Home Care (End-Use) Global Market Share Distribution by Region/Country for 2019 and 2025 |
| Hospitals (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 |
| Hospitals (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2019 VS 2025 |
| Clinics (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 |
| Clinics (End-Use) Market Share Shift across Key Geographies: 2019 VS 2025 |
| Other End-Uses (End-Use) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Other End-Uses (End-Use) Market Share Breakdown by Region/Country: 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Acute Heart Failure (AHF) Therapeutics Market Share (in %) by Company: 2020 & 2025 |
| United States Acute Heart Failure (AHF) Therapeutics Market Estimates and Projections in US$ Thousand by Product Type: 2018 to 2025 |
| United States Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| United States Acute Heart Failure (AHF) Therapeutics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Breakdown in the United States by End-Use: 2019 VS 2025 |
| Canada |
| Canadian Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
| Canadian Acute Heart Failure (AHF) Therapeutics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| Canadian Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Japan |
| Japanese Market for Acute Heart Failure (AHF) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2018-2025 |
| Japanese Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Japanese Demand Estimates and Forecasts for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Shift in Japan by End-Use: 2019 VS 2025 |
| China |
| Chinese Acute Heart Failure (AHF) Therapeutics Market Growth Prospects in US$ Thousand by Product Type for the Period 2018-2025 |
| Chinese Acute Heart Failure (AHF) Therapeutics Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
| Chinese Demand for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Chinese Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by End-Use: 2019 VS 2025 |
| Europe |
| Market Facts & Figures |
| European Acute Heart Failure (AHF) Therapeutics Market: Competitor Market Share Scenario (in %) for 2020 & 2025 |
| European Acute Heart Failure (AHF) Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| European Acute Heart Failure (AHF) Therapeutics Market Share Shift by Region/Country: 2019 VS 2025 |
| European Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018-2025 |
| European Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| European Acute Heart Failure (AHF) Therapeutics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| European Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| France |
| Acute Heart Failure (AHF) Therapeutics Market in France by Product Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 |
| French Acute Heart Failure (AHF) Therapeutics Market Share Analysis: A 7-Year Perspective by End-Use for 2019 and 2025 |
| Germany |
| Acute Heart Failure (AHF) Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| German Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in Germany by End-Use: 2019 VS 2025 |
| Italy |
| Italian Acute Heart Failure (AHF) Therapeutics Market Growth Prospects in US$ Thousand by Product Type for the Period 2018-2025 |
| Italian Acute Heart Failure (AHF) Therapeutics Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
| Italian Demand for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Italian Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by End-Use: 2019 VS 2025 |
| United Kingdom |
| United Kingdom Market for Acute Heart Failure (AHF) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2018-2025 |
| United Kingdom Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| United Kingdom Demand Estimates and Forecasts for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Shift in the United Kingdom by End-Use: 2019 VS 2025 |
| Spain |
| Spanish Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
| Spanish Acute Heart Failure (AHF) Therapeutics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| Spanish Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Russia |
| Russian Acute Heart Failure (AHF) Therapeutics Market Estimates and Projections in US$ Thousand by Product Type: 2018 to 2025 |
| Russian Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Russian Acute Heart Failure (AHF) Therapeutics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Breakdown in Russia by End-Use: 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018-2025 |
| Rest of Europe Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Rest of Europe Acute Heart Failure (AHF) Therapeutics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| Rest of Europe Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Asia-Pacific Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Region/Country: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Asia-Pacific by Product Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 |
| Asia-Pacific Acute Heart Failure (AHF) Therapeutics Market Share Analysis: A 7-Year Perspective by End-Use for 2019 and 2025 |
| Australia |
| Acute Heart Failure (AHF) Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| Australian Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in Australia by End-Use: 2019 VS 2025 |
| India |
| Indian Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in India: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
| Indian Acute Heart Failure (AHF) Therapeutics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| Indian Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| South Korea |
| Acute Heart Failure (AHF) Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in South Korea by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in South Korea by End-Use: 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Acute Heart Failure (AHF) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2018-2025 |
| Rest of Asia-Pacific Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Rest of Asia-Pacific Demand Estimates and Forecasts for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Shift in Rest of Asia-Pacific by End-Use: 2019 VS 2025 |
| Latin America |
| Latin American Acute Heart Failure (AHF) Therapeutics Market Trends by Region/Country in US$ Thousand: 2018-2025 |
| Latin American Acute Heart Failure (AHF) Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2019 and 2025 |
| Latin American Acute Heart Failure (AHF) Therapeutics Market Growth Prospects in US$ Thousand by Product Type for the Period 2018-2025 |
| Latin American Acute Heart Failure (AHF) Therapeutics Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
| Latin American Demand for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Latin American Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by End-Use: 2019 VS 2025 |
| Argentina |
| Argentinean Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018-2025 |
| Argentinean Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Argentinean Acute Heart Failure (AHF) Therapeutics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| Argentinean Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Brazil |
| Acute Heart Failure (AHF) Therapeutics Market in Brazil by Product Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Brazilian Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 |
| Brazilian Acute Heart Failure (AHF) Therapeutics Market Share Analysis: A 7-Year Perspective by End-Use for 2019 and 2025 |
| Mexico |
| Acute Heart Failure (AHF) Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| Mexican Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in Mexico by End-Use: 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Acute Heart Failure (AHF) Therapeutics Market Estimates and Projections in US$ Thousand by Product Type: 2018 to 2025 |
| Rest of Latin America Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Rest of Latin America Acute Heart Failure (AHF) Therapeutics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Breakdown in Rest of Latin America by End-Use: 2019 VS 2025 |
| Middle East |
| The Middle East Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| The Middle East Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Region/Country: 2019 and 2025 |
| The Middle East Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
| The Middle East Acute Heart Failure (AHF) Therapeutics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 |
| The Middle East Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Iran |
| Iranian Market for Acute Heart Failure (AHF) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2018-2025 |
| Iranian Acute Heart Failure (AHF) Therapeutics Market Share Analysis by Product Type: 2019 VS 2025 |
| Iranian Demand Estimates and Forecasts for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Shift in Iran by End-Use: 2019 VS 2025 |
| Israel |
| Israeli Acute Heart Failure (AHF) Therapeutics Market Estimates and Forecasts in US$ Thousand by Product Type: 2018-2025 |
| Israeli Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Israeli Acute Heart Failure (AHF) Therapeutics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 |
| Israeli Acute Heart Failure (AHF) Therapeutics Market Share Analysis by End-Use: 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Acute Heart Failure (AHF) Therapeutics Market Growth Prospects in US$ Thousand by Product Type for the Period 2018-2025 |
| Saudi Arabian Acute Heart Failure (AHF) Therapeutics Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
| Saudi Arabian Demand for Acute Heart Failure (AHF) Therapeutics in US$ Thousand by End-Use: 2018 to 2025 |
| Saudi Arabian Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by End-Use: 2019 VS 2025 |
| United Arab Emirates |
| Acute Heart Failure (AHF) Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in United Arab Emirates by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in United Arab Emirates by End-Use: 2019 VS 2025 |
| Rest of Middle East |
| Acute Heart Failure (AHF) Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2018-2025 |
| Rest of Middle East Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| Acute Heart Failure (AHF) Therapeutics Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Distribution in Rest of Middle East by End-Use: 2019 VS 2025 |
| Africa |
| African Acute Heart Failure (AHF) Therapeutics Market Estimates and Projections in US$ Thousand by Product Type: 2018 to 2025 |
| African Acute Heart Failure (AHF) Therapeutics Market Share Breakdown by Product Type: 2019 VS 2025 |
| African Acute Heart Failure (AHF) Therapeutics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 |
| Acute Heart Failure (AHF) Therapeutics Market Share Breakdown in Africa by End-Use: 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 33 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com